Literature DB >> 22309634

The role of heat in rubbing and massage-related corneal deformation.

Charles W McMonnies1, Donald R Korb, Caroline A Blackie.   

Abstract

PURPOSE: To examine the role of elevated corneal temperature in the development of rubbing/massage-related corneal deformation and the possibility that warm compresses in the management of meibomian gland dysfunction or chalazion could contribute to such adverse responses.
METHODS: With reference to reports of corneal deformation associated with meibomian gland dysfunction, chalazion, dacryocystoceles and post-trabeculectomy, the mechanisms for increased corneal temperature due to ocular massage, especially when combined with warm compresses are examined.
RESULTS: Several mechanisms for rubbing/massage to elevate corneal temperature have been described, apart from the application of warm compresses or other forms of heat.
CONCLUSIONS: Raised corneal temperature helps to explain corneal deformation which develops in association with rubbing or massage in conditions such as keratoconus, chalazion, post-trabeculectomy, post-laser assisted in situ keratomileusis, post-graft and dacryocystoceles. When combined with warm compresses or other methods of heat delivery to the eye, the elevation of corneal temperature appears to explain how meibomian gland dysfunction treatment involving warm compresses and massage could induce rubbing-related deformation. Patients whose management involves iatrogenic ocular massage appear to require screening for risk of corneal deformation. Risk may be increased for patients with a concurrent habit of rubbing their eyes abnormally in response to allergic itch for example. It appears to be possible to modify ocular massage techniques to reduce the risk of corneal deformation. Careful tutoring and follow-up using corneal topography appears to be required when massage is prescribed, especially when used in conjunction with heat application.
Copyright © 2012 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22309634     DOI: 10.1016/j.clae.2012.01.001

Source DB:  PubMed          Journal:  Cont Lens Anterior Eye        ISSN: 1367-0484            Impact factor:   3.077


  8 in total

1.  Corneal biochemical features of patients with vernal keratoconjunctivitis.

Authors:  Sinan Emre; Esin Başer; Bilge Oztürk; Sibel Zorlu; Ozgür Uzun; Ceren Gülhan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-22       Impact factor: 3.117

Review 2.  Keratoconus: an inflammatory disorder?

Authors:  V Galvis; T Sherwin; A Tello; J Merayo; R Barrera; A Acera
Journal:  Eye (Lond)       Date:  2015-05-01       Impact factor: 3.775

3.  The optimum temperature for the heat therapy for meibomian gland dysfunction.

Authors:  Douglas Borchman
Journal:  Ocul Surf       Date:  2019-02-19       Impact factor: 5.033

Review 4.  Molecular and Histopathological Changes Associated with Keratoconus.

Authors:  Mariam Lotfy Khaled; Inas Helwa; Michelle Drewry; Mutsa Seremwe; Amy Estes; Yutao Liu
Journal:  Biomed Res Int       Date:  2017-01-30       Impact factor: 3.411

5.  The Limitation of Applying Heat to the External Lid Surface: A Case of Recalcitrant Meibomian Gland Dysfunction.

Authors:  Christen J Kenrick; Sabiha S Alloo
Journal:  Case Rep Ophthalmol       Date:  2017-01-16

6.  Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary.

Authors:  Karl Stonecipher; Richard Potvin
Journal:  Clin Ophthalmol       Date:  2019-09-05

7.  Independent and interactive effects of eye rubbing and atopy on keratoconus.

Authors:  Kaili Yang; Dan Li; Liyan Xu; Chenjiu Pang; Dongqing Zhao; Shengwei Ren
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

8.  Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction-related evaporative dry eye.

Authors:  Paramdeep Singh Bilkhu; Shehzad Anjam Naroo; James Stuart Wolffsohn
Journal:  Br J Ophthalmol       Date:  2014-07-04       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.